This site is intended for healthcare professionals

Myovant Sciences has submitted an NDA to the FDA for its once-daily relugolix for the treatment of women with heavy menstrual bleeding associated with uterine fibroids.

Read time: 1 mins
Last updated:9th Dec 2020
Published:3rd Jun 2020
Condition: Uterine Fibroids
Type: drug
Register for free exclusive healthcare eLearning resources

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest